Skin cancer incidence rates are rising globally. Limitations of traditional assessment and monitoring demand a new approach, which may include the color of your eyes.

"Being there and strengthening trustful relationships." How SCARLETRED bridges medical innovation and cultural understanding between Austria and Japan. And why, in science and in business, pictures speak more than words.

Harald Schnidar, CEO & Founder of SCARLETRED, will speak at Exporttag 2026 on May 28th, 2026. Organized by the Austrian Economic Chamber (WKO), over 3.000 attendees including international speakers and experts are expected.

We are delighted to announce that SCARLETRED is the main sponsor and expertise partner of the 7th Dermatology Drug Development Summit EUROPE, showcasing Mobile Skin Imaging and ARORA®AI in Drug Development.

Bridging Austrian Innovation and Japanese Business Culture - SCARLETRED CEO and Founder Harald Schnidar to deliver keynote at the Opening Panel of this year's cherry Blossom Business and Culture Event at Vienna Airport City.

SCARLETRED was invited by MedUni Wien to the presentation of its new clinical research hub: the Center for Translational Medicine (CTM) and the Eric Kandel Institute - Center for Precision Medicine (CPM).

The International Vaccine Institute (IVI) visited the SCARLETRED Headquarters in Vienna. The joint meeting highlighted the importance of companionship and collaboration for safety, efficacy and affordability of vaccines.

Ozempic® is a GLP-1 therapy known for rapid weight loss, but it can also cause facial changes often referred to as Ozempic® Face. Scarletred® Vision allows early detection and monitoring of these changes.

SCARLETRED is honored to be featured in the dermatology-focused professional journal DermaForum - published by mgo medizin. The scientific article was additionally published in a print run of 6.500 copies.

Speaking at AUTOMA+ 2025, SCARLETRED CEO Dr. Harald Schnidar shows how SCARLETRED®Vision, a CE-certified platform, transforms dermatology with remote, clinically validated, AI-powered skin assessments.

We are proud to share that SCARLETRED has been featured by ADVANTAGE AUSTRIA as one of Austria’s leading MedTech innovators, advancing AI-powered dermatology, standardized skin imaging, and remote skin assessment.

We are proud to announce that the results of our Phase I clinical trial, conducted amid the challenges of the COVID-19 pandemic, have been published in the peer-reviewed journal Clinical Pharmacokinetics.

Scarletred is gearing up for AUTOMA+ 2025 in Vösendorf, Austria! Join us as we drive digital transformation in pharma with AI-powered dermatology. Meet our CEO Dr. Harald Schnidar, at the event!

Scarletred joins the 9th DDDS 2025 in Boston as lead partner. Meet our CEO Harald Schnidar on stage and discover Scarletred®Vision - our AI-powered dermatology platform.

We’re excited to attend the 6th ISDS in New York City! Visit our booth to experience Scarletred®Vision, explore our AI assistant “Arora”, and take part in our Discover & Win challenge.

Medtech scale-up SCARLETRED achieves a major milestone: its AI-powered skin imaging solution “Arora” enters clinical routine at LKH University Hospital Graz, setting new standards in cancer therapy and dermatology care.

SCARLETRED will attend BIO-Europe 2025 in Vienna to showcase its AI-driven digital dermatology platform, showing how skin assessment can speed clinical development, improve data quality, and support precision medicine.

Scarletred®Vision is revolutionizing care for rare skin conditions like EB, delivering AI-powered dermatology directly to patients and physicians for faster, safer, and more accessible monitoring.

Proud to unveil our latest AI-driven innovation for injection site reaction monitoring at ESDR 2025, advancing dermatology research, care, and patient outcomes.

SCARLETRED unveils Arora AI at EXPO 2025 Japan, an intelligent assistant integrated into our new service Scarletred®Vision+, automating skin disease analysis with unmatched speed, accuracy, and real-world usability.

At SCARLETRED, we observe that organizations adopt AI in distinct stages of maturity. We describe this evolution as the Three Waves of AI in Clinical Skin Imaging. Our framework helps to identify which AI wave you are on.